Clinical Investigation or PMCF? Route the Request by the Evidence Question
Choose an EU MDR clinical-investigation or PMCF service scope by the unresolved clinical question, device status, subjects, use setting and regulator-facing output.
Signals to watch
- A sponsor asks for an MDR clinical study but does not identify whether the device is CE marked or used within its intended purpose
- A manufacturer asks for a PMCF report before showing the PMCF plan, clinical evaluation gaps or activities performed
- A post-market study is described as automatically PMCF even though its objective, intervention and regulatory route remain unknown
Route the request by the unresolved evidence question, not by the word “study.” A clinical investigation systematically investigates one or more human subjects to assess a device’s safety or performance. Post-market clinical follow-up (PMCF) is a continuous process that updates the clinical evaluation by proactively collecting and evaluating clinical data from use of a CE-marked device within its intended purpose. PMCF can include a study, but “after launch” does not automatically make every investigation PMCF.
That distinction matters to a medical-device clinical services business-development lead reading authorised clinical-research, regulatory-affairs, distributor and manufacturer Telegram groups. If the request waits a day, a sponsor meeting or proposal deadline can pass before anyone has identified the actual deliverable. The business Signal is not “someone needs a study”; it is a dated evidence gap with a device, user population and regulatory decision attached.
Three requests that sound alike but open different files
These abbreviated messages are illustrative and do not describe customers or actual devices:
“Need EU clinical study quote. Device is already sold elsewhere. Protocol this quarter.”
“Notified body asked for PMCF report. We have complaints and a survey draft.”
“CE-marked software, new hospital workflow. Can this be post-market?”
None supplies the intended purpose, risk class, CE status in the Union, clinical evaluation, precise question, subject exposure, investigation objective, PMCF plan or competent-authority and ethics status. Each needs a different first document.
Request one: prove safety or performance through human-subject use
Use the clinical-investigation intake when the proposed activity is a systematic investigation involving human subjects and the objective is to assess device safety or performance. Under the Medical Devices Regulation (MDR), Articles 62–80 and Annex XV govern different investigation situations. The route changes with CE status, intended purpose, whether additional invasive or burdensome procedures occur, and national requirements.
The first service record should identify the sponsor, device and version, intended purpose, development and conformity stage, risk class, target population, investigation objective, endpoints, subject exposure, sites, investigator, comparator, monitoring approach and planned application route. It should also identify which facts are still assumptions.
The expected output may include a clinical investigation plan, investigator’s brochure, application package, monitoring records, safety reporting and a clinical investigation report. A protocol-writing quote cannot be final if the device description and clinical question are still moving.
Request two: close a named post-market clinical-evaluation gap
Use the PMCF intake when the manufacturer is maintaining clinical evidence for a CE-marked device used within its intended purpose and can identify the residual question. Annex XIV Part B describes PMCF as a continuous process that updates the clinical evaluation. Its objectives include confirming safety and performance throughout the expected lifetime, identifying previously unknown side-effects, monitoring known risks, finding emergent risks, maintaining benefit-risk acceptability and identifying possible systematic misuse or off-label use.
Start with the current clinical evaluation report, post-market surveillance plan, risk-management file and the gap the PMCF activity must address. Then inspect the PMCF plan. The MDCG 2020-7 template expects objectives, general and specific methods, rationale, references to clinical evaluation and risk management, data evaluation and a schedule.
The output is not simply “a survey.” Methods may include registries, literature, user feedback, evaluation of suitable clinical data or a PMCF study. The method must be capable of answering the named gap. Results belong in a PMCF evaluation report and feed the clinical evaluation report and technical documentation.
Request three: the post-market label is not enough
A study beginning after CE marking may still require a clinical-investigation route analysis. If a CE-marked device is studied outside its intended purpose, or the study adds procedures beyond normal conditions of use, timing alone cannot select PMCF. Conversely, a PMCF activity can involve systematic investigation and human subjects.
Ask four questions before assigning a proposal owner:
- What exact safety, performance or benefit-risk question remains?
- Is the device CE marked, and is proposed use inside the current intended purpose?
- What happens to subjects beyond ordinary device use and care?
- Which regulator-facing record must change: application file, investigation report, PMCF plan, PMCF evaluation report, clinical evaluation report or another technical-documentation section?
Those answers determine whether the first paid task is route assessment, protocol development, PMCF planning, data analysis, evaluation-report drafting or a different clinical-evidence gap review.
Compare the deliverable, not vendor feature lists
| Intake dimension | Clinical-investigation workstream | PMCF workstream |
|---|---|---|
| Primary question | Can a defined investigation generate safety or performance evidence from human subjects? | Which post-market clinical gap must be updated for the CE-marked device? |
| Starting record | Device and development status, clinical question and proposed investigation | Clinical evaluation, risk management, PMS evidence and PMCF gap |
| Typical planning output | Investigation plan and applicable submission package | PMCF plan with justified methods and schedule |
| Findings output | Clinical investigation report and related safety/monitoring records | PMCF evaluation report feeding clinical evaluation and technical documentation |
| Common routing error | Quoting protocol work before defining device, purpose and route | Calling any post-market survey or study PMCF without a clinical-evaluation gap |
The comparison is conditional. It does not state that one service is better or cheaper, and it does not replace qualified clinical, regulatory, ethics or legal review.
For registration-system timing, use the EUDAMED mandatory-use source check. The FDA QMSR and ISO 13485 gap-assessment intake shows how another medical-device request is bounded by the governing record. The pricing page covers TOP Prospect subscriptions, not clinical-service fees.
TOP Prospect can surface related fragments from authorised Telegram groups deliberately connected by the user and retain original text, source, time, cross-group support and a reason for review. Saving a matching target only stores configuration; it does not automatically run or create candidates. The product cannot inspect a technical file, select an MDR route, recruit subjects, obtain ethics approval, run a study or produce a regulatory conclusion.
Key facts
- A clinical investigation systematically investigates human subjects to assess device safety or performance.
- PMCF continuously updates the clinical evaluation after market access using a justified plan and methods.
- PMCF can include a study; post-market timing alone does not define PMCF.
- Device status, intended purpose, subject procedures and required output change the service route.
- PMCF findings are analysed in a PMCF evaluation report and feed the clinical evaluation and technical documentation.
- Unknown route, ethics and authority facts must stay explicit during commercial intake.
FAQ
Is every post-market clinical investigation a PMCF activity?
No. PMCF is selected by its purpose in the clinical-evaluation and post-market system, not merely by a start date after market access.
Can PMCF include a clinical investigation?
Yes. A PMCF plan can use post-market studies when that method answers the identified clinical-evidence gap, while applicable investigation requirements still need review.
What is the main output of PMCF?
A PMCF plan defines the questions and methods; a PMCF evaluation report analyses findings and feeds the clinical evaluation report and technical documentation.
Does a CE mark remove the need for clinical-investigation review?
No. The proposed use, objective, subject exposure and regulatory route still determine what approvals and records are required.
Editorial review completed 21 August 2026 against Regulation (EU) 2017/745, Annex XIV and the current Commission index for MDCG guidance. Qualified clinical, regulatory, ethics and legal reviewers must confirm the actual route.
Frequently asked questions
Is every post-market clinical investigation a PMCF activity?
No. PMCF is defined by its purpose within the post-market surveillance and clinical-evaluation system. Timing after market access alone does not establish that a study is PMCF.
Can PMCF include a clinical investigation?
Yes. Annex XIV Part B lists evaluating suitable clinical data from equivalent or similar devices and post-market studies among possible PMCF methods, while the applicable clinical-investigation requirements still need review.
What is the main output of PMCF?
The manufacturer documents methods in a PMCF plan and findings in a PMCF evaluation report, which becomes part of the clinical evaluation report and technical documentation.
Does a CE mark remove the need for clinical-investigation review?
No. Device status, intended purpose, study objective, subject exposure and the applicable MDR route still have to be established.
Sources and further reading
How a Signal worth attention is found
See how Top Prospect finds and organizes Signals worth checking, keeps the original Telegram context, removes duplicates, and helps you decide what to review first. You decide whether to follow up and what to do next.
